by Marybeth Burke – The investigational drug BMS-936558 caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and NSCLC cancers,
by Marybeth Burke – Afatinib, an irreversible ErbB-family blocker, delays progression of advanced lung cancer in patients with epidermal growth factor receptor (EGFR) mutations compared with standard chemotherapy,
Second study sheds light on the ‘obesity paradox’ People can be obese but metabolically healthy and fit, with no greater risk of developing or dying from cardiovascular disease… read more.
Second study sheds light on the ‘obesity paradox’ People can be obese but metabolically healthy and fit, with no greater risk of developing or dying from cardiovascular disease… read more.
by Maria Dalby – Introduction – In many ways waiting lists to receive an organ transplantation look very much the same today as they did a decade ago… read more.
The European Society for Medical Oncology (ESMO) has awarded ESMO Designated Center of Integrated Oncology and Palliative Care accreditation to 16 new oncology centres.
Malignant cells that leave a primary tumor, travel the bloodstream and grow out of control in new locations cause the vast majority of cancer deaths.
Sleep apnoea severity has been associated with increased cancer mortality in a new study.
by Bruce Sylvester – Obese persons who are metabolically healthy and fit have no more risk of developing or dying from cardiovascular disease or cancer than persons of… read more.
In a press release on August 8, 2012, Amgen announced that the company was halting a late-stage trial of its monoclonal antibody IGF-1 receptor antagonist ganitumab (AMG-479).
In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab emtansine) offers… read more.
by Zara Qadir reporting on the presentation by Yechiel Hekster (pictured), Professor of Clinical Pharmacy, and a member of The Netherlands Medicines Evaluation Board.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
